BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30321230)

  • 41. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
    Lobo J; Rodrigues Â; Antunes L; Graça I; Ramalho-Carvalho J; Vieira FQ; Martins AT; Oliveira J; Jerónimo C; Henrique R
    Urol Oncol; 2018 Apr; 36(4):161.e7-161.e17. PubMed ID: 29174711
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.
    Minner S; Wittmer C; Graefen M; Salomon G; Steuber T; Haese A; Huland H; Bokemeyer C; Yekebas E; Dierlamm J; Balabanov S; Kilic E; Wilczak W; Simon R; Sauter G; Schlomm T
    Prostate; 2011 Feb; 71(3):281-8. PubMed ID: 20809553
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
    Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy.
    Shariat SF; Svatek RS; Kabbani W; Walz J; Lotan Y; Karakiewicz PI; Roehrborn CG
    BJU Int; 2008 Jan; 101(2):232-7. PubMed ID: 17868422
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues.
    Merseburger AS; Kuczyk MA; Serth J; Bokemeyer C; Young DY; Sun L; Connelly RR; McLeod DG; Mostofi FK; Srivastava SK; Stenzl A; Moul JW; Sesterhenn IA
    Oncol Rep; 2003; 10(1):223-8. PubMed ID: 12469173
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Annexin A7 deficiency potentiates cardiac NFAT activity promoting hypertrophic signaling.
    Voelkl J; Alesutan I; Pakladok T; Viereck R; Feger M; Mia S; Schönberger T; Noegel AA; Gawaz M; Lang F
    Biochem Biophys Res Commun; 2014 Feb; 445(1):244-9. PubMed ID: 24508799
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer.
    Flammiger A; Weisbach L; Huland H; Tennstedt P; Simon R; Minner S; Bokemeyer C; Sauter G; Schlomm T; Trepel M
    Eur J Cancer; 2013 Apr; 49(6):1273-9. PubMed ID: 23266046
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High NRBP1 expression in prostate cancer is linked with poor clinical outcomes and increased cancer cell growth.
    Ruiz C; Oeggerli M; Germann M; Gluderer S; Stocker H; Andreozzi M; Thalmann GN; Cecchini MG; Zellweger T; Stürm S; Koivisto PA; Helin HJ; Gelmann EP; Glass AG; Gasser TC; Terracciano LM; Bachmann A; Wyler S; Bubendorf L; Rentsch CA
    Prostate; 2012 Nov; 72(15):1678-87. PubMed ID: 22473923
    [TBL] [Abstract][Full Text] [Related]  

  • 50. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Survival of patients with laryngeal cancer and some prognostic factors].
    Gryczyński M; Kobos J; Murlewska A; Pietruszewska W
    Otolaryngol Pol; 2003; 57(3):329-40. PubMed ID: 14524174
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinicopathological and prognostic significance of p53, Ki-67, and Bcl-2 expression in Tunisian gastric adenocarcinomas.
    Ayed DB; Khabir A; Abid M; Bayrouti MI; Gargouri A; Sellami-Boudawara T; Mokdad-Gargouri R
    Acta Histochem; 2014 Oct; 116(8):1244-50. PubMed ID: 25095748
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of annexin A7 gene and protein induces the apotosis and decreases the invasion, migration of the hepatocarcinoma cell line.
    Huang Y; Wang Q; Du Y; Bai L; Jin F; Zhang J; Fan S; Wang H; Song L; Gao Y; Wang X; Tang J
    Biomed Pharmacother; 2014 Sep; 68(7):819-24. PubMed ID: 25070395
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
    Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
    Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification.
    Yang Z; Tang LH; Klimstra DS
    Am J Surg Pathol; 2011 Jun; 35(6):853-60. PubMed ID: 21566513
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.
    Fleischmann A; Schlomm T; Huland H; Köllermann J; Simon P; Mirlacher M; Salomon G; Chun FH; Steuber T; Simon R; Sauter G; Graefen M; Erbersdobler A
    Clin Cancer Res; 2008 Dec; 14(23):7838-42. PubMed ID: 19047112
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
    Moul JW
    Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.
    Zheng Y; Lin ZY; Xie JJ; Jiang FN; Chen CJ; Li JX; Zhou X; Zhong WD
    Curr Mol Med; 2017; 17(3):221-229. PubMed ID: 28782483
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Annexin A3 is associated with a poor prognosis in breast cancer and participates in the modulation of apoptosis in vitro by affecting the Bcl-2/Bax balance.
    Zeng C; Ke Z; Song Y; Yao Y; Hu X; Zhang M; Li H; Yin J
    Exp Mol Pathol; 2013 Aug; 95(1):23-31. PubMed ID: 23631820
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cyclin E and FGF8 are downstream cell growth regulators in distinct tumor suppressor effects of ANXA7 in hormone-resistant cancer cells of breast versus prostate origin.
    Bera A; Leighton XM; Pollard H; Srivastava M
    Trends Cancer Res; 2018; 13():55-62. PubMed ID: 30369774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.